Roivant Sciences Ltd Total Liabilities
Roivant Sciences Ltd total liabilities. Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has total liabilities worth $251.14 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ROIV defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Roivant Sciences Ltd (2019–2025)
Total liabilities of Roivant Sciences Ltd from 2019 to 2025. This chart illustrates how Roivant Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Roivant Sciences Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Roivant Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of Roivant Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telia Company AB
ST:TELIA
|
Sweden | Skr134.43 Billion |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
USA | $63.21 Billion |
|
Victory Giant Technology Huizhou Co Ltd
SHE:300476
|
China | CN¥25.12 Billion |
|
NN Group NV
AS:NN
|
Netherlands | €183.76 Billion |
|
Raiffeisen Bank International AG
VI:RBI
|
Austria | €200.18 Billion |
|
NiSource Inc
NYSE:NI
|
USA | $25.64 Billion |
|
US Foods Holding Corp
NYSE:USFD
|
USA | $9.83 Billion |
|
Synnex Corporation
NYSE:SNX
|
USA | $29.56 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Roivant Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Roivant Sciences Ltd assets under control.
Liquidity & Leverage Metrics
Roivant Sciences Ltd Total Liabilities Ratios Explained
Roivant Sciences Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roivant Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roivant Sciences Ltd (2019–2025)
The table below shows the annual total liabilities of Roivant Sciences Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $249.74 Million | -67.73% |
| 2024-03-31 | $773.95 Million | -1.03% |
| 2023-03-31 | $782.02 Million | +49.33% |
| 2022-03-31 | $523.70 Million | -0.76% |
| 2021-03-31 | $527.69 Million | +43.25% |
| 2020-03-31 | $368.36 Million | -18.24% |
| 2019-03-31 | $450.51 Million | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more